I don’t know if they do it, because no independent researchers examine those swabs, but I have always pointed out that our overlords seem more concerned with testing than with vaccinating. Almost like the vaccines were the bait and tests were the switch. And now we also know they totally CAN do that. Just follow the science below.
November 3, 2020
Researchers engineer tiny machines that deliver medicine efficiently
Inspired by a parasitic worm that digs its sharp teeth into its host’s intestines, Johns Hopkins researchers have designed tiny, star-shaped microdevices that can latch onto intestinal mucosa and release drugs into the body.
David Gracias, Ph.D., a professor in the Johns Hopkins University Whiting School of Engineering, and Johns Hopkins gastroenterologist Florin M. Selaru, M.D., director of the Johns Hopkins Inflammatory Bowel Disease Center, led a team of researchers and biomedical engineers that designed and tested shape-changing microdevices that mimic the way the parasitic hookworm affixes itself to an organism’s intestines.
Made of metal and thin, shape-changing film and coated in a heat-sensitive paraffin wax, “theragrippers,” each roughly the size of a dust speck, potentially can carry any drug and release it gradually into the body.
The team published results of an animal study this week as the cover article in the journal Science Advances.
Gradual or extended release of a drug is a long-sought goal in medicine. Selaru explains that a problem with extended-release drugs is they often make their way entirely through the gastrointestinal tract before they’ve finished dispensing their medication.
“Normal constriction and relaxation of GI tract muscles make it impossible for extended-release drugs to stay in the intestine long enough for the patient to receive the full dose,” says Selaru, who has collaborated with Gracias for more than 10 years. “We’ve been working to solve this problem by designing these small drug carriers that can autonomously latch onto the intestinal mucosa and keep the drug load inside the GI tract for a desired duration of time.”
Thousands of theragrippers can be deployed in the GI tract. When the paraffin wax coating on the grippers reaches the temperature inside the body, the devices close autonomously and clamp onto the colonic wall. The closing action causes the tiny, six-pointed devices to dig into the mucosa and remain attached to the colon, where they are retained and release their medicine payloads gradually into the body. Eventually, the theragrippers lose their hold on the tissue and are cleared from the intestine via normal gastrointestinal muscular function.
Gracias notes advances in the field of biomedical engineering in recent years.
“We have seen the introduction of dynamic, microfabricated smart devices that can be controlled by electrical or chemical signals,” he says. “But these grippers are so small that batteries, antennas and other components will not fit on them.”
Theragrippers, says Gracias, don’t rely on electricity, wireless signals or external controls. “Instead, they operate like small, compressed springs with a temperature-triggered coating on the devices that releases the stored energy autonomously at body temperature.”
The Johns Hopkins researchers fabricated the devices with about 6,000 theragrippers per 3-inch silicon wafer. In their animal experiments, they loaded a pain-relieving drug onto the grippers. The researchers’ studies found that the animals into which theragrippers were administered had higher concentrates of the pain reliever in their bloodstreams than did the control group. The drug stayed in the test subjects’ systems for nearly 12 hours versus two hours in the control group.
Context: Brain disorders remain the world’s leading cause of disability, and account for more hospitalizations and prolonged care than almost all other diseases combined. The majority of drugs, proteins and peptides do not readily permeate into brain due to the presence of the blood-brain barrier (BBB), thus impeding treatment of these conditions.
Objective: Attention has turned to developing novel and effective delivery systems to provide good bioavailability in the brain.
Methods: Intranasal administration is a non-invasive method of drug delivery that may bypass the BBB, allowing therapeutic substances direct access to the brain. However, intranasal administration produces quite low drug concentrations in the brain due limited nasal mucosal permeability and the harsh nasal cavity environment. Pre-clinical studies using encapsulation of drugs in nanoparticulate systems improved the nose to brain targeting and bioavailability in brain. However, the toxic effects of nanoparticles on brain function are unknown.
Result and conclusion: This review highlights the understanding of several brain diseases and the important pathophysiological mechanisms involved. The review discusses the role of nanotherapeutics in treating brain disorders via nose to brain delivery, the mechanisms of drug absorption across nasal mucosa to the brain, strategies to overcome the blood brain barrier, nanoformulation strategies for enhanced brain targeting via nasal route and neurotoxicity issues of nanoparticles.
Epub 2013 Oct 16.
Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting
The central nervous system (CNS) is an immunological privileged sanctuary site-providing reservoir for HIV-1 virus. Current anti-HIV drugs, although effective in reducing plasma viral levels, cannot eradicate the virus completely from the body. The low permeability of anti-HIV drugs across the blood-brain barrier (BBB) leads to insufficient delivery. Therefore, developing a novel approaches enhancing the CNS delivery of anti-HIV drugs are required for the treatment of neuro-AIDS. The aim of this study was to develop intranasal nanoemulsion (NE) for enhanced bioavailability and CNS targeting of saquinavir mesylate (SQVM). SQVM is a protease inhibitor which is a poorly soluble drug widely used as antiretroviral drug, with oral bioavailability is about 4%. The spontaneous emulsification method was used to prepare drug-loaded o/w nanoemulsion, which was characterized by droplet size, zeta potential, pH, drug content. Moreover, ex-vivo permeation studies were performed using sheep nasal mucosa. The optimized NE showed a significant increase in drug permeation rate compared to the plain drug suspension (PDS). Cilia toxicity study on sheep nasal mucosa showed no significant adverse effect of SQVM-loaded NE. Results of in vivo biodistribution studies show higher drug concentration in brain after intranasal administration of NE than intravenous delivered PDS. The higher percentage of drug targeting efficiency (% DTE) and nose-to-brain drug direct transport percentage (% DTP) for optimized NE indicated effective CNS targeting of SQVM via intranasal route. Gamma scintigraphy imaging of the rat brain conclusively demonstrated transport of drug in the CNS at larger extent after intranasal administration as NE.
Over the past few years, nasal drug delivery has attracted more and more attentions, and been recognized as the most promising alternative route for the systemic medication of drugs limited to intravenous administration. Many experiments in animal models have shown that nanoscale carriers have the ability to enhance the nasal delivery of peptide/protein drugs and vaccines compared to the conventional drug solution formulations. However, the rapid mucociliary clearance of the drug-loaded nanoparticles can cause a reduction in bioavailability percentage after intranasal administration. Thus, research efforts have considerably been directed towards the development of hydrogel nanosystems which have mucoadhesive properties in order to maximize the residence time, and hence increase the period of contact with the nasal mucosa and enhance the drug absorption. It is most certain that the high viscosity of hydrogel-based nanosystems can efficiently offer this mucoadhesive property. This update review discusses the possible benefits of using hydrogel polymer-based nanoparticles and hydrogel nanocomposites for drug/vaccine delivery through the intranasal administration.
Nanoparticles for nasal vaccination. Csaba N, Garcia-Fuentes M, Alonso MJ.Csaba N, et al.Adv Drug Deliv Rev. 2009 Feb 27;61(2):140-57. doi: 10.1016/j.addr.2008.09.005. Epub 2008 Dec 13.Adv Drug Deliv Rev. 2009.PMID: 19121350 Review.
UK’s Government’s Medicines & Healthcare products Regulatory Agency (MHRA) spends close to $2million on an Artificial Intelligence to monitor “Medicines & Healthcare products Regulatory Agency”. If this isn’t alarming, I don’t know what is. But I know there’s more to the story.
The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.
Thanks Graham Pick for the tip!
The acquisition document further provides this explanation:
“For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.
Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.
Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.
Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.”
Beneficiary of this contract is a company named Genpact, part of a larger multi-industry group with the same name. Genpact also does Facebook moderation, which gives it access to Facebook data!
Genpact CEO is close to our old friends from WEF, of course
Here he supports using military to distribute the vaccine that will then provide work for his company:
He seems to applaud a Biden victory in the US presidentials. :
This Tyger dude basically has all the traits and inclinations of the elite mafia that set up Covidiocracy as the new business and live-stock management model for the whole world.
Genpact has acquired 23 companies, including 10 in the last 5 years. A total of 8 acquisitions came from private equity firms. Genpact’s largest acquisition to date was in 2011, when it acquired Headstrong for $550M. Genpact has acquired in 11 different US states, and 5 countries. The Company’s most targeted sectors include information technology (28%) and software (28%). – Mergr
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
One of the most maleficent characters in Trump’s menagerie is this psychopath he named as leader of Operation Warp Speed, Moncef Slaoui, former GSK and Moderna boss having a bigger body count than the Spanish Flu. Actually Kushner picked him in Trumps name, but anyway, after we wrote extensive viral exposes on his past, a team of “specialists” brushed up his online presence and then he laid low for a while. But his silence is over and his newest interviews confirm everything we’ve wrote about him and Covid-19.
For the best understanding of this article, you have to read it as a follow up to four previous pieces that are anyway essential readings:
“If you take the first Operation Warp Speed vaccine you will get an unexpected surprise: micromanaged tracking by Big Tech for up to two years, who will know more about you than you know about yourself. There is no guarantee that tracking will stop after two years.” writes Technocracy News
” It should become apparent that the military/industrial complex that is running Warp Speed is functionally merged with Big Tech like Google and Oracle. And then, there is the federal government itself that is driving the entire vaccination program”, adds TN and they’re not wrong.
Moncef Slaoui, the official head of Operation Warp Speed, told the Wall Street Journal last week that all Warp Speed vaccine recipients in the US will be monitored by “incredibly precise . . . tracking systems” for up to two years and that tech giants Google and Oracle would be involved.
Last week, a rare media interview given by the Trump administration’s “Vaccine Czar” offered a brief glimpse into the inner workings of the extremely secretive Operation Warp Speed (OWS), the Trump administration’s “public-private partnership” for delivering a Covid-19 vaccine to 300 million Americans by next January. What was revealed should deeply unsettle all Americans.
During an interview with the Wall Street Journal published last Friday, the “captain” of Operation Warp Speed, career Big Pharma executive Moncef Slaoui, confirmed that the millions of Americans who are set to receive the project’s Covid-19 vaccine will be monitored via “incredibly precise . . . tracking systems” that will “ensure that patients each get two doses of the same vaccine and to monitor them for adverse health effects.” Slaoui also noted that tech giants Google and Oracle have been contracted as part of this “tracking system” but did not specify their exact roles beyond helping to “collect and track vaccine data.”
The day before the Wall Street Journal interview was published, the New York Times published a separate interview with Slaoui where he referred to this “tracking system” as a “very active pharmacovigilance surveillance system.” During a previous interview with the journal Science in early September, Slaoui had referred to this system only as “a very active pharmacovigilance system” that would “make sure that when the vaccines are introduced that we’ll absolutely continue to assess their safety.” Slaoui has only recently tacked on the words “tracking” and “surveillance” to his description of this system during his relatively rare media interviews.
While Slaoui himself was short on specifics regarding this “pharmacovigilance surveillance system,” the few official documents from Operation Warp Speed that have been publicly released offer some details about what this system may look like and how long it is expected to “track” the vital signs and whereabouts of Americans who receive a Warp Speed vaccine.
This is basically what we meant by “It’s about data and vaccines” in our headline above. And 5G will follow Covid around because all this data needs carried by a medium and many antennas. Which, while doing their work, can also produce Covid-like symptoms, as a bonus benefit for the Covidiocracy orchestrators.
The Last American Vagabond takes it from here into finer details in one of his latest posts, demonstrating we’re guinea pigs and this is how they will study us:
Two official OWS documents released in mid-September state that vaccine recipients—expected to include a majority of the US population—would be monitored for twenty-four months after the first dose of a Covid-19 vaccine is administered and that this would be done by a “pharmacovigilance system.”
In the OWS document entitled “From the Factory to the Frontlines,” the Department of Health and Human Services (HHS) and the Department of Defense (DOD) stated that, because Warp Speed vaccine candidates use new unlicensed vaccine production methods that “have limited previous data on safety in humans . . . the long-term safety of these vaccines will be carefully assessed using pharmacovigilance surveillance and Phase 4 (post-licensure) clinical trials.”
The key objective of pharmacovigilance is to determine each vaccine’s performance in real-life scenarios, to study efficacy, and to discover any infrequent and rare side effects not identified in clinical trials. OWS will also use pharmacovigilance analytics, which serves as one of the instruments for the continuous monitoring of pharmacovigilance data. Robust analytical tools will be used to leverage large amounts of data and the benefits of using such data across the value chain, including regulatory obligations.
In addition, Moncef Slaoui and OWS’s vaccine coordinator, Matt Hepburn, formerly a program manager at the Pentagon’s controversial Defense Advanced Research Projects Agency (DARPA), had previously published an article in the New England Journal of Medicine that stated that “because some technologies have limited previous data on safety in humans, the long-term safety of these vaccines will be carefully assessed using pharmacovigilance surveillance strategies.”
The use of pharmacovigilance on those who receive the vaccine is also mentioned in the official Warp Speed “infographic,” which states that monitoring will be done in cooperation with the Food and Drug Administration (FDA) and the Centers for Disease Control and Protection (CDC) and will involve “24 month post-trial monitoring for adverse effects.”
In a separate part of that same document, OWS describes one of its “four key tenets” as “traceability,” which has three goals: to “confirm which of the approved vaccines were administered regardless of location (private/public)”; to send a “reminder to return for second dose”; and to “administer the correct second dose.”
Regarding a Covid-19 vaccine requiring more than one dose, a CDC document associated with Operation Warp Speed states:
For most Covid-19 vaccine products, two doses of vaccine, separated by 21 or 28 days, will be needed. Because different Covid-19 vaccine products will not be interchangeable, a vaccine recipient’s second dose must be from the same manufacturer as their first dose. Second-dose reminders for vaccine recipients will be critical to ensure compliance with vaccine dosing intervals and achieve optimal vaccine effectiveness.
The CDC document also references a document published in August by the Johns Hopkins Center for Health Security, associated with the Event 201 and Dark Winter simulations, as informing its Covid-19 vaccination strategy. The Johns Hopkins paper, which counts Dark Winter co-organizer Thomas Inglesby as one of its authors, argues that existing “passive reporting” systems managed by the CDC and FDA should be retooled to create “an active safety surveillance system directed by the CDC that monitors all [Covid-19] vaccine recipients—perhaps by short message service or other electronic mechanisms.”
Despite the claims in these documents that the “pharmacovigilance surveillance system” would intimately involve the FDA, top FDA officials stated in September that they were barred from attending OWS meetings and told reporters they could not explain the operation’s organization or when or with what frequency its leadership meets. The FDA officials did state, however, that they “are still allowed to interact with companies developing products for OWS,” STAT news reported.
In addition, the FDA has apparently “set up a firewall between the vast majority of staff and the initiative [Operation Warp Speed]” that appears to drastically limit the number of FDA officials with any knowledge of or involvement in Warp Speed. The FDA’s director of the Center for Drug Evaluation and Research, Janet Woodcock, is the only FDA official listed as having any direct involvement in OWS and appears to be personally managing this “firewall” at the FDA. Woodcock describes herself as a long-time advocate for the use of “big data” in the evaluation of drug and vaccine safety and has been intimately involved in FDA precursors to the coming Warp Speed “pharmacovigilance surveillance system” known as Sentinel and PRISM, both of which are discussed later in this report.
Woodcock is currently on a temporary leave of absence from her role as the director of the Center for Drug Evaluation and Research, which allows her to focus her complete attention on overseeing aspects of Operation Warp Speed on behalf of the FDA’s Office of the Commissioner. Her temporary replacement at the FDA, Patrizia Cavazzoni, is “very aligned with Janet and where the agency is going,” according to media reports. Cavazzoni is a former executive at Pfizer, one of the companies producing a vaccine for OWS. That vaccine is set to begin testing in children as young as 12 years old.
The extreme secrecy of Operation Warp Speed has affected not only the FDA but also the CDC, as a CDC expert panel normally involved in developing the government’s vaccine distribution strategies was “stonewalled” by Matt Hepburn, OWS’s vaccine coordinator, who bluntly refused to answer several of the panel’s “pointed questions” about the highly secretive operation.
More Secret Contracts
While Moncef Slaoui and Warp Speed documents provide few details regarding what this “tracking system” would entail, Slaoui did note in his recent interview with the Wall Street Journal that tech giants Google and Oracle had been contracted to “collect and track vaccine data” as part of this system. Neither Google nor Oracle, however, has announced receipt of a contract related to Operation Warp Speed, and the DOD and HHS, similarly, have yet to announce the awarding of any Warp Speed contract to either Google or Oracle. In addition, searches on the US government’s Federal Register and on the official website for federally awarded contracts came up empty for any contract awarded to Google or Oracle that would apply to any such “pharmacovigilance” system or any other aspect of Operation Warp Speed.
Given my previous reporting on the use of a nongovernment intermediary for awarding OWS contracts to vaccine companies, it seems likely that Warp Speed contracts awarded to Google and Oracle were made using a similar mechanism. In an October 6, 2020, report for The Last American Vagabond, I noted that $6 billion in Warp Speed contracts awarded to vaccine companies were made through Advanced Technology International (ATI), a government contractor that works mainly with the military and surveillance technology companies and whose parent company has strong ties to the CIA and the 2001 Dark Winter simulation. HHS, which is supposedly overseeing Operation Warp Speed, claimed to have “no record” of at least one of those contracts. Only one Warp Speed vaccine contract, which did not involve ATI and was awarded directly by HHS’s Biomedical Advanced Research and Development Authority, was recently obtained by KEI Online. Major parts of the contract, however, including the section on intellectual property rights, were redacted in their entirety.
If the Warp Speed contracts that have been awarded to Google and Oracle are anything like the Warp Speed contracts awarded to most of its participating vaccine companies, then those contracts grant those companies diminished federal oversight and exemptions from federal laws and regulations designed to protect taxpayer interests in the pursuit of the work stipulated in the contract. It also makes them essentially immune to Freedom of Information Act (FOIA) requests. Yet, in contrast to the unacknowledged Google and Oracle contracts, vaccine companies have publicly disclosed that they received OWS contracts, just not the terms or details of those contracts. This suggests that the Google and Oracle contracts are even more secretive.
A major conflict of interest worth noting is Google’s ownership of YouTube, which recently banned on its massive multimedia platform all “misinformation” related to concerns about a future Covid-19 vaccine. With Google now formally part of Operation Warp Speed, it seems likely that any concerns about OWS’s extreme secrecy and the conflicts of interest of many of its members (particularly Moncef Slaoui and Matt Hepburn) as well as any concerns about Warp Speed vaccine safety, allocation and/or distribution may be labeled “Covid-19 vaccine misinformation” and removed from YouTube.
From the NSA to the FDA: The New PRISM
Though the nature of this coming surveillance system for Covid-19 vaccine recipients has yet to be fully detailed by Warp Speed or the tech companies the operation has contracted, OWS documents and existing infrastructure at the FDA offer a clue as to what this system could entail.
For instance, the Warp Speed document “From the Factory to the Frontlines” notes that the pharmacovigilance system will be a new system created exclusively for OWS that will be “buil[t] off of existing IT [information technology] infrastructure” and will fill any “gaps with new IT solutions.” It then notes that “the Covid-19 vaccination program requires significant enhancement of the IT that will support enhancements and data exchange that are critical for a multi-dose candidate to ensure proper administration of a potential second dose.” The document also states that all data related to the OWS vaccine distribution effort “will be reported into a common IT infrastructure that will support analysis and reporting,” adding that this “IT infrastructure will support partners with a broad range of tools for record-keeping, data on who is being vaccinated, and reminders for second doses.”
Though some Warp Speed documents hint as to the existing IT systems that will serve as the foundation for this new tracking system, arguably the most likely candidate is the FDA-managed Sentinel Initiative, which was established in 2009 during the H1N1 Swine flu pandemic. Like Operation Warp Speed itself, Sentinel is a public-private partnership and involves the FDA, private business, and academia.
According to its website, Sentinel’s “main goal is to improve how FDA evaluates the safety and performance of medical products” through big data, with an additional focus on “learning more about potential side effects.” Media reports describe Sentinel as “an electronic surveillance system that aggregates data from electronic medical records, claims and registries that voluntarily participate and allows the agency to track the safety of marketed drugs, biologics and medical devices.”
One of Sentinel’s main proponent at the FDA is Janet Woodcock, who has aggressively worked to expand the program as director of the FDA’s Center for Drug Evaluation and Research, with a focus on Sentinel’s use in “post-market effectiveness studies.” As previously mentioned, Woodcock is the only FDA official listed among the ninety or so “leaders” of OWS, most of whom are part of the US military and lack any health-care or vaccine-production experience.
Woodcock’s temporary replacement at the FDA, Patrizia Cavazzoni, is also very active in efforts to expand Sentinel. STAT news reported earlier this year that Cavazzoni previously “served on the sterling committee of I-MEDS, an FDA-industry partnership which allows drug makers to pay for use of the FDA’s real-world data system known as Sentinel to complete certain safety studies more quickly.”
Sentinel has a series of “collaborating partners” that “provide healthcare data and scientific, technical, and organizational expertise” to the initiative. These collaborating partners include intelligence contractor Booz Allen Hamilton, tech giant IBM, and major US health insurance companies such as Aetna and Blue Cross Blue Shield, among many others. In addition, Sentinel’s Innovation Center, which it describes as the program’s “test bed to identify, develop, and evaluate innovative methods,” is partnered with Amazon, General Dynamics, and Microsoft. Sentinel also has a Community Building and Outreach Center, which is managed by Deloitte consulting, one of the largest consultancy firms in the world that is known for seeking to fill its ranks with former CIA officials.
The Sentinel system’s specific surveillance program aimed at monitoring vaccine effectiveness is known as the Post-licensure Rapid Immunization Safety Monitoring Program, better known as PRISM. Sentinel’s PRISM was “developed to monitor vaccine safety, but [to date] has never been used to assess vaccine effectiveness.” PRISM was initially launched alongside the Sentinel Initiative itself in 2009 “in response to the need to monitor the safety of the H1N1 influenza vaccine” after it was licensed, marketed, and administered. Yet, as previously mentioned, PRISM has yet to be used to assess the effectiveness of any vaccine while quietly expanding for nearly a decade, which implies that the stakeholders in the Sentinel Initiative have a plan to implement this “safety surveillance system” at some point.
The name PRISM may remind readers of the National Security Agency (NSA) program of the same name that became well known throughout the United States following the Edward Snowden revelations. Given this association, it is worth noting that the NSA, as well as the Department of Homeland Security (DHS), are now officially part of Operation Warp Speed and appear to be playing a role in the development of Warp Speed’s “pharmacovigilance surveillance system.” The addition of the NSA and the DHS to the initiative, of course, greatly increases the involvement of US intelligence agencies in the operation, which itself is “dominated” by the military and sorely lacking in civilian public health officials.
CyberScoop first reported in early September that members of the NSA’s Cybersecurity Directorate were involved in Operation Warp Speed, with their role—as well as that of DHS—being framed mainly as offering “cybersecurity advice” to the initiative. However, the NSA and DHS are also offering “guidance” and “services” to both the other federal agencies involved in Warp Speed as well as OWS contractors, which now include Google and Oracle.
People started to think the meme it’s just that, as no one seemed to get a hold of the paper in either physical or digital form. We have found the whole publication on archive.org, in PDF, Download right here ! Regardless of our opinions on the content, this is part of the popular culture .
Depopulation Through Forced Vaccination:
The Zero Carbon Solution
By Rachel Windeer. (First published June 2011 in Issue 4 of The Sovereign independent)
On April 26th, 2009 the Irish Independent published an article titled ‘Concern for Children’s Health as Parents ignoring vaccines’. Edel Kennedy, you should be ashamed of yourself! This is nothing less than an attempt by government, through their puppets in the media, to remove the rights of parents to determine the life choices of their offspring and removes any doubt that we now live in a dictatorship.
This is an OUTRAGEOUS insult to every parent in the country who has the common sense to research the efficacy of vaccines themselves by simply looking at the historical record rather than trust politicians whose lies in the media, including those perpetrated by the Dept. of Health under Mary Harney regarding the farce of ‘ swine flu’ and the dangerous myth of HPV vaccination, have led the country into the abyss of utter poverty and sold the country into the communist grasp of European bureaucrats whose sole aim is the destruction of every member nation’s sovereignty leaving them clutching at the bailout begging bowl of the IMF.
Vaccines are a fraud; pure and simple!
The historical record PROVES this for anyone with a little patience and the courage to investigate the FACTS for themselves, and it does take courage, especially for those in the medical profession whose careers will be at risk if they dare expose this danger to our children. It also shatters their illusions that they’re part of an organization which is far from beneficial to those they believe they’ re protecting from illness. However, their Hypocratic Oath should compel them to investigate such wild claims put out by pharmaceutical giants and their drug dealer sales representatives instead of taking the word of an industry well known as being utterly corrupt and ruthless in its business practices.
The Irish haemophiliac scandal, where patients were knowingly infected with HIV through contaminated blood products should be enough to convince anyone of Big Pharma’s murderous intent. This brings us to the real reasons for vaccinations. I’m not even going to prove to readers that they don’t work. I’ll simply urge you to look up the historical record. One simple example is the demise of measles.
The measles death rate had declined by 98% from 1915-1958 prior to any vaccination being introduced.
In 1988 and 1989, 69% and 89% for measles cases in American school-aged children had been vaccinated.
In 1995, 56% of ALL measles cases in America were vaccinated.
These figures come from medical journals. Those 3 simple examples PROVE that unvaccinated children are less likely to contract measles and that the vaccine was useless. Look that up for yourself. All other vaccine claims that they’ve cured or eliminated disease follow a similar pattern. Better hygiene, clean water and good healthy food was the cause of the decline and any doctor worth his smelling salts should know that. If they don’t then they are misinformed on a grand scale or they’re in complete denial. Therein lies the problem. Why have doctors been ‘indoctrinated’ to believe that vaccines are the sacred cow of medicine when the historical record clearly shows that they are virtually useless?
Hold onto your sanity because I have some bad news for you.
The real reason for vaccinations, apart from the massive profits to the manufacturers, is to ensure that you get sick throughout your life, again not only to enrich these same corporations that made you sick, but to ensure that many, if not all of you, die before you ever receive your pension and when you are no longer any of use to society. That’s why they want you retiring later in life and are forcing you through economic terrorism to work longer regardless of your age or health. They literally want to work you to death. If you don’t work you will be classed as a burden to society, a financial cost which society has to bear, and therefore you will be stigmatised as a ‘useless eater’; a consumer of resources needed for the rest of society. When Big Pharma can no longer profit from the illness they gave you, you will be left to die.
This is the depopulation agenda promoted under the United Nations Division of Population under the Department of Economic and Social Affairs. We only need look at Africa, the nation which the United Nations has said themselves, could feed the world. Why then are millions in Africa starving to death on that continent? It’s meant to be that way folks.
All of us at one time or another have been led to believe in the efficacy of vaccines. I was one of them and had my child vaccinated nearly 35 years ago. I wouldn’t even dream of it now. I think it’s safe to say that we’re all aware of the real pandemic, as opposed to the fake pandemics of the past. It’s called ‘CANCER’. Autism is also at crisis (pandemic) levels all across the world where mass vaccination programs exist.
Prior to mass vaccination, cancers were extremely rare, as in almost nonexistent. Today in the western, so called developed world, we face a crisis of cancer to the extent that between one in five to one in two will suffer, many dying, from one form of cancer or another. What’s happened to cause this pandemic?
We only have to look back at the Jonas Salk polio vaccine that went around the world in the full knowledge that it contained the SV40 virus which had no other purpose than causing cancer; yet it was pushed as a vaccine for polio when, as with measles, polio was well in decline prior to any vaccine due to the same factors.
Enter stage right at the TED 201 0 conference, Mr. Bill Gates, head of Microsoft, the biggest computer firm on the planet. What has Bill Gates to do with vaccines you’ re wondering?
See the quote in the image above. Those are his EXACT words. Are you beginning to get the picture?
The globalist elite care nothing for humanity; ordinary men, women and children must be eliminated in their delusional minds to ensure that their superior types go into the future with the best of breeding being the only criteria worthy of saving. You and I are no longer required and that is why we are seeing the loss of our economy, our wealth, our health, our happiness and ultimately, OUR LIVES
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
This has been revealed to me while investigating Trump’s new “Vaccine Czar” Moncef Slaoui, in his home-town Agadir, Morocco, under a coronavirus lockdown and a hunger-strike. Energy and time are scarce, I’ll be making a brief sum-up here, and for more details please read my other investigations on this site.
The scheme is simple and efficient:
Bill Gates: Money, influence and organizing
Tony Fauci (NIAID): Influence, research and power
through US Government and media with all their capabilities
Moncef Slaoui (GSK, Moderna), US’ new “Vaccine Czar”: concocts the vaccines, connects the industry
Together they control WHO and GAVI, which serve as common platforms and global marketers
The following vaccines have been elaborated and marketed by this group, mostly with disastrous effects:
“This is not the big game changer that we were hoping for,” said Dr. Martin De Smet, a malaria expert at Doctors Without Borders. “The vaccine itself remains disappointing but this is an important step forward,” he said. Still, De Smet said the vaccine could help reduce the huge burden of malaria: there are about 200 million cases and more than 500,000 deaths every year, mostly in African children.
“Higher OR*s were observed within the vaccinated versus unvaccinated group for developmental delays, asthma and ear infections. No association was found for gastrointestinal disorders in the primary analysis, but a significant relationship was detected in the third and fourth quartiles (where more vaccine doses were administered), at the 6-month cut-off in the temporal analysis, and when time permitted for a diagnosis was extended from children ⩾ 3 years of age to children ⩾ 5 years of age. Similar results have been observed in earlier studies by Mawson et al. and Delong.”. This are the results of a study published by Sage Journals only two days ago.
OR = oddis ratio = a ratio showing the strength of an association. Hiher OS = stronger association / higher prevalence / higher incidence
Using data from three medical practices in the United States with children born between November 2005 and June 2015, vaccinated children were compared to unvaccinated children during the first year of life for later incidence of developmental delays, asthma, ear infections and gastrointestinal disorders. The study, published May 27, 2020 by Sage Journals, is titled “Analysis of health outcomes in vaccinated and unvaccinated children: Developmental delays, asthma, ear infections and gastrointestinal disorders“ and was conducted last year by Brian S Hooker, Department of Sciences and Mathematics, Simpson University, and Neil Z Miller, Institute of Medical and Scientific Inquiry, Santa Fe, Dr Hooker is a paid scientific advisor and serves on the advisory board for Focus for Health (formerly Focus Autism). He also serves on the Board of Trustees for Children’s Health Defense (formerly World Mercury Project) and is a paid independent contractor of Children’s Health Defense as well. Dr Hooker is the father of a 22-year old male who has been diagnosed with autism and developmental delays. Mr Miller is the director of Thinktwice Global Vaccine Institute and was a paid consultant to Physicians for Informed Consent.
This study employed a cohort study design with strata for medical practice, year of birth and gender. Cases were evaluated against non-cases for an association between vaccination status and the different health conditions considered. In general, with a sample size of approximately 2000 subjects, the study was designed to have a power of 80% to detect odds ratios of 1.8 (α = 0.05 and a confidence level of 0.95), but because of some more rare diagnoses, 80% power in select instances was only sufficient to detect odds ratios of 2.4 and above.
The study couldn’t analyse illnesses with low incidences because the sample was too low. That means insufficient data.
The strongest relationships observed for vaccination status were for asthma, developmental delays and ear infections (Table 4). Although the association between vaccinations and asthma in males was elevated (Table 5), it should be noted that there were only three asthma cases in the unvaccinated group. No association between vaccinations and asthma in females was found ; this may also be due to just four asthma cases in the unvaccinated group. Although some studies were unable to find correlations between vaccines and asthma, a relationship between vaccination and allergy/atopy incidence (including asthma) has been reported. In a study involving Korean children who were all vaccinated against hepatitis B, a significantly higher asthma incidence was seen among children who had actually seroconverted to produce anti-HepB.In addition, Hurwitz and Morgenstern reported an association between diphtheria–tetanus–pertussis (DTP) and tetanus toxoid vaccination and allergy symptoms and could not rule out a relationship with asthma. In an animal study, mice vaccinated according to the Chinese infant vaccine schedule showed airway hyperresponsiveness at a significantly higher rate than unvaccinated mice.
The IOM Immunization Safety Review Committee conducted an evaluation regarding thimerosal-containing vaccines and concluded that “the hypothesis that exposure to thimerosal-containing vaccines could be associated with neurodevelopment disorders” was biologically plausible. Mawson et al. found a relationship between vaccination status and learning disability and neurodevelopmental disorders. Delong also reported a significant relationship to neurodevelopmental disorders (autism and speech and language delay) when looking at the proportions of vaccine uptake in US children. Other research, focused more on the uptake of specific vaccines, has elucidated such relationships. Gallagher and Goodman saw a greater number of boys receiving special education services if they had received the entire hepatitis B vaccine series in infancy. Geier et al. also documented a link between neurodevelopmental disorders and thimerosal-containing vaccines. (Although thimerosal has been phased out of most vaccines administered in the United States, it still remains in some formulations of the influenza vaccine given to pregnant women and infants.)
Mawson et al. reported a significant relationship between vaccination status and ear infections. Wilson et al. found that for both males and females, top reasons for emergency room visits and/or hospital admissions after their 12-month vaccinations included ear infections and non-infective gastroenteritis or colitis. Prior to the RotaTeq rotavirus vaccine achieving FDA approval, 71,725 infants were evaluated in three placebo-controlled clinical trials. Otitis media (middle ear infection) occurred at a statistically higher incidence (p < 0.05) within 6 weeks of any dose among the recipients of RotaTeq as compared with the recipients of placebo.
In this study, which only allowed for the calculation of unadjusted observational associations, higher ORs were observed within the vaccinated versus unvaccinated group for developmental delays, asthma and ear infections. Further study is necessary to understand the full spectrum of health effects associated with childhood vaccination.
Also important from the conclusion note of the study: “The findings in this study must be weighed against the strengths and limitations of the available data and study design, which only allowed for the calculation of unadjusted observational associations. Additional research utilizing a larger sample from a variety of pediatric medical practices will yield greater certainty in results and allow for the investigation of health conditions with lower prevalence, such as autism. A thorough evaluation of vaccinated versus unvaccinated populations is essential to understanding the full spectrum of health effects associated with specific vaccines and the childhood vaccine schedule in totality.”
One of the main strengths of this study is that the data are based directly on patient chart records and diagnosis codes. Practitioners making these diagnoses were also directly available for consultation on how specific diagnosis codes were applied. In addition, vaccination records were based on patient chart data, although coding practices for vaccination varied among the three different pediatric practices. To account for any differences in diagnosing among the three different practices, cases and non-cases were stratified based on medical practice. Thus, no “cross comparisons” were made among two or more medical practices. To account for differences in likelihood of particular diagnoses based on the age and gender of the patient, cases and non-cases were stratified based on the year of birth and gender.
It is possible that diagnoses may have been missed or information regarding vaccines administered could have been incorrectly recorded leading to exposure misclassification, which might explain the high rates of unvaccinated children in the cohort. However, all children considered in the study were enrolled in their medical practice from birth and followed up continuously to minimum age cut-offs of 3 years and 5 years. This minimized the risk of missing vaccination doses or diagnoses associated with tracking patients with multiple practitioners. This also eliminated recall bias associated with studies focused on parental surveys. The high proportion of unvaccinated children is most likely indicative of pediatric practices which accepted unvaccinated and partially vaccinated children into their case load.
The main weakness of this study is the use of a convenience sample of three different pediatric practices. In addition, the size of the sample, although sufficient for some diagnoses, such as the five main conditions studied, was too small for analysis of conditions with lower prevalence, such as autism. Also, this sample may not accurately represent a cross-section of US children given the low incidence of autism (0.5%) and ADD/ADHD (0.7%) compared to incidences observed nationwide (at 1.7%and between 5% and 9%, respectively). In addition, vaccine uptake, which is approximately 95% nationwide, is rather low in these practices and may reflect demographic differences between the study sample and the general population. Also, due to different coding practices among the three caseloads studied, we were unable to differentiate between the types of vaccinations given. This limited the analysis to counting the number of vaccinations received by 1 year of age.
The low level of vaccine uptake overall in these practices (mean = 8.9 vaccines by 1 year of age) obviates our ability to do a comparison between fully vaccinated and unvaccinated children within this cohort. Also, the median age at first vaccine dose in the cohort was 81 days (just under 3 months) as compared to the hepatitis B vaccine that is recommended within 24 h of birth. Medical chart records did not include specific demographic factors that may be associated with health outcomes, including socioeconomic status, maternal education, gestational age at birth, Appearance, Pulse, Grimace, Activity and Respiration (APGAR) score, type of birth and duration of breastfeeding, among others. In brief: insufficient data for laser-precision. Which doesn’t deny the main observation
Vaccination is considered to be one of the most important advances in modern public health.1 Currently, children between birth and 6 years of age receive up to 36 vaccine doses to protect against 14 different diseases, according to the Centers for Disease Control and Prevention’s (CDC) recommended schedule. By ages 1 and 2 years, the CDC recommends approximately 21 and 28 such vaccination doses, respectively. The number of vaccine doses received by infants and children has increased most notably since the early 1990s, when the hepatitis B and Haemophilus influenzae type B vaccines were introduced. Currently, children in the United States are vaccinated for hepatitis A and B, Haemophilus influenzae type B, diphtheria, pertussis, tetanus, polio, measles, mumps, rubella, rotavirus, pneumococcal pneumonia, influenza and varicella.
Although short-term clinical testing is completed on individual vaccines (with limited longer-term follow-up for specific vaccine adverse events) prior to approval by the US Food and Drug Administration (FDA), the health outcomes related to these vaccines and the vaccination schedule as a whole are largely unknown. For instance, Kuter et al. detailed 23 different post-licensing trials conducted on the measles, mumps and rubella (MMR)-II vaccine and in no instance were the patients followed for more than 42 days post-vaccination. In 2011, the Institute of Medicine (IOM) published the report “Adverse Effects of Vaccines: Evidence and Causality” where the relationships between specific vaccines and different adverse health effects were considered. Based on the current scientific literature, the IOM committee found inadequate evidence to accept or reject a causal relationship between 135 of 158 relationships between vaccines and adverse events. Among the remaining 23 adverse events, 18 were found to be associated with vaccination and 5 were not.
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
The medical community does in general acknowledge that vaccination is not without health risks, including death. However, it is widely purported that these side effects or “adverse events” are extremely rare and justified compared to the overall benefit of vaccination.7 There have been very few studies reported where health effects of the US infant and childhood vaccination schedule have been assessed. This is in part based on ethical concerns of withholding vaccination from an unvaccinated control group within such a study. Indeed, this precludes the use of double-blinded placebo studies on vaccine health effects, and even in clinical trials an earlier version of the same vaccine is often used as the placebo control for the newly tested vaccine.
One study, published by Mawson et al., was based on a convenience sample of homeschooled children where a significant portion of the sample (39%) was unvaccinated. In this small sample, vaccinated children showed higher odds of being diagnosed with pneumonia, otitis media, allergies and neurodevelopmental disorders. In addition, preterm birth coupled with vaccination significantly increased the odds of a neurodevelopmental disorder diagnosis. This study was unique in the inclusion of entirely unvaccinated populations to provide a comparison to partially vaccinated and fully vaccinated children. However, the risk of bias is high when comparing vaccinated versus unvaccinated children. Also, health outcomes were based on parental survey, not confirmed by medical chart review, and may be subject to recall bias, and the small size of the sample (666 patients) made it difficult to analyze for rare disorders.
Between 2001 and 2004, the IOM Immunization Safety Review Committee rejected a relationship between multiple vaccinations and sudden infant death syndrome (SIDS) but could not rule out a relationship with other types of “sudden unexpected infant death.” This included the neonatal hepatitis B vaccine as well as the diphtheria and tetanus toxoids and whole-cell pertussis (DTwP) vaccine, which was strongly associated with anaphylaxis but is no longer given in the United States. A relationship between multiple vaccines and type 1 diabetes was ruled out, but evidence was inadequate to accept or reject a relationship with asthma. In addition, the committee rejected a relationship between multiple vaccines and increased “heterologous” infections, such as bacterial infections unrelated to vaccine-preventable diseases, although recent studies have provided evidence of both beneficial and detrimental non-specific effects associated with several vaccines. The remainder of the IOM Immunization Safety Review Committee focused on single types of vaccines and specific adverse events as recommended by the CDC who commissioned these studies.
! Articles can always be subject of later editing as a way of perfecting them
In 2013, the Chinese authorities branded the international pharma giant GSK a “criminal godfather”, accusing it of running a £320m slush fund to bribe doctors and hospital officials with cash payments and visits to prostitutes. – The Guardian American public couldn’t care much, but those events built up to Moncef Slaoui‘s nomination as Trump’s “vaccine czar”
If corruption was a company, it would be GlaxoSmithKline (GSK) with “Trump’s new vaccine czar”, Moncef Slaoui, at the helms of Research and Vaccines departments. It all peaked in 2010-2015 with some of the most sordid scandals people have ever ignored. Many will pay attention now, when things escalated to truly painful levels.
GlaxoSmithKline (GSK) can trace its roots back to a small apothecary in 18th Century London. Through multiple corporate mergers, GSK found its current form in 2001. It is well-known for its asthma inhalers like Advair and Breo. They have been constantly embroidered in scandals long before 2001. Suffice for now to mention a case of actual officially-recorded conspiracy, as reported by New York Times: In 1996 SmithKline Beecham was one of 15 drug companies that together agreed to pay more than $408 million to settle a class action lawsuit charging them with conspiring to fix prices they charged to thousands of independent pharmacies. In addition to contributing $30 million to the financial settlement, SmithKline agreed to supply the plaintiffs with a quantity of the generic version of its Tagamet ulcer medication worth $20 million.
We’re not going to review every GSK case in this investigation, just the truly spectacular and relevant ones from the more recent times, when the Research & Development and Vaccines departments were under Moncef Slaoui’s command. A new name to most, the Moroccan scientist has been dubbed by US media “Trump’s vaccine czar”, a few days back, when the US president made him co-chief of Operation Warp Speed, the coronavirus mass-vaccination campaign about to start in US.
GSK has began to break records with its penalties and settlements in 2006, when it promised “it would pay $3.1 billion to the U.S. Internal Revenue Service to resolve a 17-year dispute over the tax treatment of transactions between the company’s U.S. operation and the parent company. The settlement, the largest in IRS history, focused on the issue of transfer pricing—a method by which transnational corporations artificially reduce their tax liabilities”, as New York TImes reported
Anthony Faucci, Trump’s Vaccine Czar Moncef Slaoui and WHO collaborated on the H1N1 scamdemic of 2009, a rehearsal for the Plandemic of 2020. Their vaccine destroyed thousands of children
“As chief of vaccines at GSK, Slaoui oversaw the development of the disastrous Pandemrix vaccine for swine flu, a shot that was rushed to market without proper testing in the midst of a 2009 epidemic, during which public health officials were shrieking about enormous death tolls that never materialized, with some claiming the death toll would rival the 1918 influenza pandemic (sound familiar?).” RT reported recently in a quite superficial review of the H1N1 scandal of 2009. Let me give you the full picture.
A couple of recent articles by Prof Michel Chossudovsky for Global Research make a great review of the H1N1 2009 scamdemic, greatly completing my work. Chossudovsky practices practices the same old-school document-based style of journalism I was trained too, so I will copiously quote his work in this chapter, with regards and acknowledgements :
Based on incomplete and scanty data, the WHO Director General nonetheless predicted with authority that: “as many as 2 billion people could become infected over the next two years — nearly one-third of the world population.” (World Health Organization as reported by the Western media, July 2009).
It was a multibillion bonanza for Big Pharma supported by the WHO’s Director-General Margaret Chan,(wife of a high Chinese government official – Silview’s note).
In June 2009, Margaret Chan made the following statement:
Millions of doses of swine flu vaccine had been ordered by national governments from Big Pharma. Millions of vaccine doses were subsequently destroyed: a financial bonanza for Big Pharma, an expenditure crisis for national governments.(Global Research)
The media went immediately into high gear (without a shred of evidence). Fear and Uncertainty. Public opinion was deliberately misled
“Swine flu could strike up to 40 percent of Americans over the next two years and as many as several hundred thousand could die if a vaccine campaign and other measures aren’t successful.” (Official Statement of Obama Administration, Associated Press, 24 July 2009).
“The U.S. expects to have 160 million doses of swine flu vaccine available sometime in October”, (Associated Press, 23 July 2009)
Wealthier countries such as the U.S. and Britain will pay just under $10 per dose [of the H1N1 flu vaccine]. … Developing countries will pay a lower price.” [circa $40 billion for Big Pharma?] (Business Week, July 2009)
What was most governments’ vaccine of choice? Pandemrix, elaborated by Moncef Slaoui and GlaxoSmithKline
But the H1N1 pandemic never happened. There was no pandemic affecting 2 billion people…
The H1N1 scamdemic was endorsed in US by the CDC and the NIAID headed by Dr. Anthony Fauci. NIAID Director Fauci also endorsed Moncef Slaoui’s Pandemrix vaccine, which turned out to be a multi-billion dollar life-ruining scam:
The Pandemrix vaccine made by GlaxoSmithKline (GSK) was given to 6 million people in Britain and millions more across Europe during the 2009-10 swine flu pandemic, but was withdrawn when doctors noticed a rise in narcolepsy cases among those who received the jab.
Narcolepsy is a permanent condition that can cause people to fall asleep dozens of times a day, even when they are in mid-conversation. Some suffer from night terrors and a problem with muscular control called cataplexy that can lead them to collapse on the spot. (Guardian, September 25, 2015)
In UK, the result of the hasty approval process was an unsafe, ineffective shot that left over a thousand recipients permanently brain-damaged, some 80 percent of them children. Forty percent of NHS staffers were vaccinated under false pretenses, told the shot was safe and effective. The UK government was forced to pay out millions of pounds in compensation, as GSK had refused to supply the drug to governments until it was indemnified against lawsuits.
“The Pandemrix vaccine, made by GlaxoSmithKline, was given to high-risk groups, including children and those with asthma, diabetes and heart disease at the height of the 2009-10 swine flu pandemic. Across Europe, around 31 million people received the jab. The vaccine was made specifically to tackle pandemics and is very different to the normal seasonal flu vaccine which has not been linked to narcolepsy.
The condition is a rare but serious neurological disorder that affects about 31,000 people in Britain. The condition can cause massive sleep disruption. The worst hit are often young people who face enormous learning difficulties at school and university. The disorder can destroy self-esteem, and bullying is common. Adults can lose their jobs, their driving licences, and can have difficulties with relationships. Some narcoleptics have another condition called cataplexy, a total loss of muscle control.” – The Guardian 2013
In June, a 12-year-old boy was awarded £120,000 by a court that ruled he had been left severely disabled by narcolepsy caused by Pandemrix. The win ended a three-year battle with the government that argued his illness was not serious enough to warrant compensation.
The increased risk of narcolepsy after vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine indicates a causal association, consistent with findings from Finland. – British Medical Journal
A Department of Health spokesperson said: “Pandemrix was developed specifically for use in a flu pandemic when the number of lives lost and serious cases could have been enormous.” “The decision to recommend that children got this vaccine during the flu pandemic was based on evidence available at the time, along with the advice from the European Medicines Agency which approved its use.
The government is expected to receive a bill of approximately £60 million, with each of the 60 victims expected to receive about £1 million each.
Peter Todd, a lawyer who represented many of the claimants, told the Sunday Times: “There has never been a case like this before. The victims of this vaccine have an incurable and lifelong condition and will require extensive medication.”
Following the swine flu outbreak of 2009, about 60 million people, most of them children, received the vaccine.
It was subsequently revealed that the vaccine, Pandemrix, can cause narcolepsy and cataplexy in about one in 16,000 people, and many more are expected to come forward with the symptoms.
Across Europe, more than 800 children are so far known to have been made ill by the vaccine.
In a bitter irony, it was the UK Government (rather than GSK) that paid for the Vaccine Brain Damages in Children.
But the Brain Damage impacts documented in the UK and EU was but the tip of the iceberg.
Thousands of people got sick from the H1N1 Vaccine (reported and unreported cases).
GSK’s ArepanrixTD applied in Canada
The WHO’s H1N1 pandemic was declared in June 11, 2009. GSK was on contract to the Canadian government. The GSK’s ArepandrixTM vaccine was delivered to Canadian health authorities within less than four months.
Within four months?. Does that give them Time to Test????
Lots of people in Canada fell sick after receiving the H1N1 ArepanrixTD vaccine.
And that vaccine killed a little girl called Amina Abu, which then led to a ten year lawsuit against GSK.
A vaccine was rushed to market, and the five year old was among millions of Canadians to get the shot, amid widespread fears about the new pathogen.
Five days later, Amina’s older brother found her lying unconscious in the bathroom of the family’s east-end Toronto home. She was dead.
Her devastated parents came to blame the flu shot itself and sued the vaccine’s manufacturer, Glaxo Smith Kline (GSK), for $4.2 million. The little-noticed trial of that lawsuit drew toward a close on Tuesday, a rare judicial airing in Canada of a vaccine’s alleged side effects.
The parents’ lawyer, Jasmine Ghosn, alleged the preventive drug was brought out quickly and without proper testing during a chaotic flu season, as the federal government exerted “intense pressure” on Canadians to get immunized. (National Post, November 2019)
It took ten years for a judgment. The Family lost. GSK declined responsibility for her death. And the Canadian government reimbursed GSK’s legal expenses.
That lawsuit against GSK should be reopened. Canada’s government bears the burden of responsibility.
ArepanrixTD (2009) vs PandemrixTM (2009)
GSK has casually acknowledged that the ArepanrixTD which was used in Canada is “similar” to the GSK’s PandemrixTM applied in the UK and the EU, which led to brain damage in Children. It was subsequently withdrawn. But ArepandrixTD applied in Canada prevailed. An ArepandrixTD (2010) was subsequently released the following year (and compared to PandemrixTD (2009)
GSK acknowledges that PandemrixTD (2009) causes narcolepsy, which is categorized as “a chronic neurological disorder that affects the brain’s ability to control sleep-wake cycles.”
3. To date, how many people/children in Canada have reported developing narcolepsy after getting vaccinated with Arepanrix? What provinces do they reside in Canada?
GSK reports all cases of adverse events which the company is aware of in accordance with national and regional regulations. We respectfully defer to the Public Health Agency of Canada to address this question in more detail.
4. We read that there is currently a Canadian study sponsored by GSK to assess the risk of occurrence of narcolepsy following the administration of Arepanrix – Why did you sponsor that study? When will the results of that study be published?
We are currently supporting a study that is being conducted in Quebec where Arepanrix™ (H1N1) was used. Further research is needed to evaluate the potential association between GSK`s adjuvanted H1N1 pandemic flu vaccine and narcolepsy in a country where a similar vaccine to Pandemrix™ (H1N1) was used, and where a more robust assessment of the potential association could be conducted, using a design aimed at limiting the impact of biases. The preliminary results of this study are anticipated to be published by early 2014.
There was no investigation into who was behind this multibillion fraud. Several critics said that the H1N1 Pandemic was “Fake”
The Parliamentary Assembly of the Council of Europe (PACE), a human rights watchdog, is publicly investigating the WHO’s motives in declaring a pandemic. Indeed, the chairman of its influential health committee, epidemiologist Wolfgang Wodarg, has declared that the “false pandemic” is “one of the greatest medicine scandals of the century.” (Forbes, February 10, 2010)
The World Health Organization’s handling of the swine flu pandemic was deeply marred by secrecy and conflict of interest with drug companies, a top medical journal said Friday.
The British Medical Journal, or BMJ, found that WHO guidelines on the use of antiviral drugs were prepared by experts who had received consulting fees from the top two manufacturers of these drugs, Roche and GlaxoSmithKline, or GSK.
In apparent violation of its own rules, the WHO did not publicly disclose these conflicts when the guidelines were drawn up in 2004, according to the report, jointly authored by the London-based non-profit Bureau of Investigative Journalism.
The WHO’s advice led governments worldwide to stockpile vast quantities of antivirals, and its decision to declare a pandemic in June 2009 triggered the purchase of billions of dollars worth of hastily manufactured vaccines.
Much of these stocks have gone unused because the pandemic turned out to be far less lethal than some experts feared, fueling suspicion that Big Pharma exerted undue influence on WHO decisions.
The report also reveals that at least one expert on the secret, 16-member “emergency committee” formed last year to advise the WHO on whether and when to declare a pandemic received payment during 2009 from GSK.
Announcing that swine flu had become a global pandemic automatically triggered latent contracts for vaccine manufacture with half-a-dozen major pharmaceutical companies, including GSK. The WHO has refused to identify committee members, arguing that they must be shielded from industry pressure. “The WHO’s credibility has been badly damaged,” BMJ editor Fiona Godlee said in an editorial.
In 2010, after 8 years of legal battles, it’s sentenced to pay $96 to a whistle-blower. who exposed serious contamination problems at GlaxoSmithKline’s (GSK) pharmaceutical manufacturing operations.
“Cheryl Eckard’s payment is thought to be the biggest ever handed to a US whistleblower. It was awarded after an eight-year fight, which ended yesterday, when GSK agreed to pay the US government $750m to settle civil and criminal charges that it manufactured and sold adulterated drug products.” – The Guardian
One may argue the cases above may speak volumes about GSK, but this not Slaoui’s department, he probably had nothing to do with it. Yes, he may have not had his own hands in these particular scandal, but wait for it, as you will see, corruption is the norm at GSK, not something you can easily overlook, so unless he was forced to work for this corruption galore, he was an accomplice, at least ethically and morally, as all his colleagues are. We get to Slaoui’s departments shortly.
Year 2012 finds GSK experimenting on Argentina’s poorest babies. Moncef Slaoui’s people were going to Argentina’s most disparaged areas, tracking and tricking the poorest and most illiterate people to allow vaccine trials on their kids and babies. 14 deaths ensued. “The firm failed to get proper consent from the children’s parents before injecting Synflorix, one of its bestselling vaccines, according to a judge in Buenos Aires. GSK was also criticised for keeping inadequate records of the children’s ages, medical histories and previous jabs. Evidence from Argentina’s medical regulator said that, in a few cases, scientists working for GSK relied on permission from under-age parents or illiterate grandparents, The Times reported. GSK and two of the scientists who led the trial have been fined a total of one million pesos (£150,000). Jorge Yabkowsky, president of the Argentine Federation of Health Professionals, told The Times: “These are people who depend entirely on the state apparatus and who are most often illiterate.” – The Telegraph
“The Argentinian Federation of Health Professionals accuses drug maker GlaxoSmithKline of misleading participants and pressuring poor families into joining a trial for the Synflorix vaccine, which the company says protects against bacterial pneumonia and meningitis.”They recruited children in an irregular manner. … They did not do what they were supposed to. They did not inform. There were not independent witnesses. They pressured the mothers of poor children,” said Jorge Yabkowsky, the federation’s director.” – CNN
The trial, known as Compas, involved 15,000 Argentine babies and 9,000 in Colombia and Panama. It started five years before this scandal and continued long after, despite the fine, because that’s just “cost of business” on Planet Pharma.
But that was peanuts to GSK’s budget. considering same year, 2012, they paid a $3bn (£1.8bn) fine for misselling drugs in the US, “Largest Health Care Fraud Settlement in U.S. History” in the words of US Department of Justice. DOJ further stated: <<GSK agreed to plead guilty to a three-count criminal information, including two counts of introducing misbranded drugs, Paxil and Wellbutrin, into interstate commerce and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration (FDA). Under the terms of the plea agreement, GSK will pay a total of $1 billion, including a criminal fine of $956,814,400 and forfeiture in the amount of $43,185,600. The criminal plea agreement also includes certain non-monetary compliance commitments and certifications by GSK’s U.S. president and board of directors. GSK’s guilty plea and sentence is not final until accepted by the U.S. District Court.
GSK will also pay $2 billion to resolve its civil liabilities with the federal government under the False Claims Act, as well as the states. The civil settlement resolves claims relating to Paxil, Wellbutrin and Avandia, as well as additional drugs, and also resolves pricing fraud allegations.
“Today’s multi-billion dollar settlement is unprecedented in both size and scope. It underscores the Administration’s firm commitment to protecting the American people and holding accountable those who commit health care fraud,” said James M. Cole, Deputy Attorney General. “At every level, we are determined to stop practices that jeopardize patients’ health, harm taxpayers, and violate the public trust – and this historic action is a clear warning to any company that chooses to break the law.”>>
Rewind that: A Deputy Attorney General said in a DOJ press release that GSK “jeopardized patients’ health, harmed taxpayers, and violated the public trust“.
You think that’s bad? Reading further in the DOJ press release we find out that Bill Corr, Deputy Secretary of the Department of Health and Human Services (HHS) really called it out:
“cheaters who thought they could make an easy profit at the expense of public safety, taxpayers, and the millions of Americans who depend on programs like Medicare and Medicaid”
“GSK, one of the world’s largest healthcare and pharmaceuticals companies, admitted to promoting antidepressants Paxil and Wellbutrin for unapproved uses, including treatment of children and adolescents. The illegal practice is known as off-label marketing. The company also conceded charges that it held back data and made unsupported safety claims over its diabetes drug Avandia. It agreed to resolve civil liability for promoting asthma drug Advair and two lesser-known drugs for unapproved uses.
In addition, GSK has been found guilty of paying kickbacks to doctors.” – BBC
“The sales force bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts”
The public hardly got scandalized and mostly by the bribes, but the most serious crime is the one committed by Slaoui’s department, Forbes being one of the very few media that nailed this: “Keeping safety data secret: Federal investigators say that between 2001 and 2007, GlaxoSmithKline failed to disclose safety data from certain studies of Avandia to the Food and Drug Administration. This is, ethically, perhaps the most serious of the charges. Glaxo’s handling of the Avandia matter was fraught with bad disclosure bordering on deceit. During that time period, Avandia became the best-selling diabetes drug in the world. Now it not only bears warnings that it might cause heart attacks, its use has been so restricted that the drug has nearly vanished off Glaxo’s ledgers. To the extent that Glaxo kept Avandia’s heart risk from being recognized, that means that patients were exposed to added risks. For this, Glaxo is paying a fine of $243 million.”
As part of the settlement, GSK agreed to be monitored by US government officials for five years. Only to see the company embroiled in another humongous scandal within a year, as they re-based their corruption in China.
The 2013 scandal “started with sex tapes of the company’s China head, Mark Reilly and his Chinese girlfriend at a Shanghai department, which were sent to several senior executives of the company. The company’s investigations into the sex tapes made the paid investigator Peter Humphrey and his wife Yu Yingzeng in jail in China due to their breach of privacy law. With the bribery scandal made public by the Chinese police since June 2013, GSK had to admit its pervasive corruption in China. After tried in Changsha in September 2014, the company apologized to the Chinese people, and paid one of the biggest fines in Chinese history worth ¥3bn (£300m; €350m; $490m).4 executives of the company, including Mark Reilly, the only foreign citizens involved, were sentenced to jail. Reilly was deported from China as well. The sequent US Securities and Exchange Commission investigation was settled by GSK with a $20 million civil penalty in 2016, yet the UK Serious Fraud Office failed to finish the expensive investigation which was officially ended in 2019.” Wikipedia
The corruption at GSK was multi-levelled and ubiquitous, it wasn’t just bribes for sales, that’s why the scandal needed about 5 years to find closure, more or less. GSK board received an email in January 2013 where how China’s branch committed fraud in its operations was detailedly described in 5,200 words. The email was well written in English. The email said that GSK China disguised tourist travel in the disguise of international academic meetings. The company paid for the airline tickets and hotel rooms for such meetings to bribe Chinese medical professionals. The email continued by accusing GSK China of falsifying its books and records to illegally market drugs in China. The whistleblower made examples by the drug Lamictal, which was approved in China only for treating epilepsy, but was marketed as a drug for bipolar disorder aggressively. The drug killed a patient due to false marketing, but GSK chose to pay around 9,000 US dollars to silence the patient.
From 2013’s ScienceMag we find out that “accusations of data fabrication at GlaxoSmithKline’s China research site are quite real. That’s what we get from the latest developments in the case, as reported by BioCentury, Pharmalot, and the news section at Nature Medicine. Jingwu Zang, lead author on the disputed paper and former head of the Shanghai research site, has been dismissed from the company. Other employees are on administrative leave while an investigation proceeds, and GSK has said it has begun the process of retracting the paper itself. As for what’s wrong with the paper in question, BioCentury Extra has this:
GSK said data in a paper published in January 2010 in Nature Medicine on the role of interleukin-7 (IL-7) in autoimmune disease characterized data as the results of experiments conducted with blood cells of multiple sclerosis (MS) patients “when, in fact, the data reported were either the results of experiments conducted at R&D China with normal (healthy donor) samples or cannot be documented at all, suggesting that they well may have been fabricated.”
The pharmaceutical giant’s head of global research & development at the time, Moncef Slaoui, received a total remuneration package of $8.4m for his work in 2013, up from $6.6m in 2012.“
Moncef Slaoui was very close to the Chinese GSK division because, as I pointed out in my previous article, in 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million. This was one of his biggest projects at GSK, so much of his time and energy were spent through at the China branch. Slaoui’s megalomaniac plans failed miserably and ceased operations in August 2017, which is the most probable cause of his departure from GSK same year.
The following year, 2014, “the pay packets of finance boss Simon Dingemans and vaccines head Moncef Slaoui also took a hit last year. Mr Dingemans received £1.9m, down from £3.3m the year before. Dr Slaoui got $4.3m (£2.8m), compared with his $8.4m remuneration in 2013.”, reported The Telegraph. GSK had to recover from one of the biggest fines in history!
“China has fined UK pharmaceuticals firm GlaxoSmithKline $490m (£297m) after a court found it guilty of bribery” – BBC, 2014
<<The record penalty follows allegations the drug giant paid out bribes to doctors and hospitals in order to have their products promoted. The court gave GSK’s former head of Chinese operations, Mark Reilly, a suspended three-year prison sentence and he is set to be deported. Other GSK executives have also been given suspended jail sentences.
Chinese authorities first announced they were investigating GSK in July last year (2013 – the year Slaoui was cashing big bonuses – Silview’s note), in what has become the biggest corruption scandal to hit a foreign firm in years. The company was accused of having made an estimated $150m in illegal profits.
GSK said it had “published a statement of apology to the Chinese government and its people”.
“Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK,” said chief executive Sir Andrew Witty in a statement. “We have and will continue to learn from this. GSK has been in China for close to a hundred years and we remain fully committed to the country and its people,” he said. “We will also continue to invest directly in the country to support the government’s health care reform agenda and long-term plans for economic growth.”
Mick Cooper, analyst at Edison Investment Research in London, said: “GlaxoSmithKline will hope that this will draw a line under events in China, but it will take time for its Chinese commercial operations to recover.>> – BBC, 2014
US authorities then investigated whether GSK breached the Foreign Corrupt Practices Act, while the UK’s Serious Fraud Office (SFO) launched a formal criminal investigation into its overseas practices in May. “The SFO criminal investigation into the commercial practices of GlaxoSmithKline and its subsidiaries continues,” a spokeswoman at the SFO told Reuters in 2014.
Funnily, this event is what changed Slaoui’s course of life and made him a candidate for Trump’s Operation Warp speed. Because the scandal shook GSK’s hierarchies, with Slaoui moving from R&D to heading the vaccines branch.
Did a any of that slow the corruption machine down, did they ever stop? On 2014-15 they were also investigating other allegations that GSK paid incentives to secure sales of its products in countries including Romania, Syria, Poland, Iraq, Jordan, UAE and Lebanon.
GlaxoSmithKline PLC is investigating allegations of bribery by employees in the Middle East, according to emails reviewed by The Wall Street Journal, opening a new front for the company as it manages a separate corruption probe in China.
A person familiar with Glaxo’s Mideast operations emailed the U.K. drug company late last year and earlier this year to report what the person said were corrupt practices in Iraq, including continuing issues and alleged misconduct dating from last year and 2012″
The Guardian, April 7th 2014: “GSK looking into claims that it hired 16 Iraqi government doctors and pharmacists to improperly boost its sales Details of the allegations, which are said to have originated in 2012 but continue to this day, were sent to company executives by a whistleblower, according to the Wall Street Journal. The emails claim the alleged malpractice breaches the UK’s Bribery Act and the US Foreign Corrupt Practices Act, which ban bribery of foreign officials.”
The Guardian, April 14th 2014 “GSK acknowledged the Polish allegations dating from 2010 after an investigation by the BBC’s Panorama programme GlaxoSmithKline, the British drug company embroiled in bribery scandals in China and Iraq, has been accused of bribing doctors in Poland in the latest corruption furore to hit the business. The company, which has made a series of public promises to “root out corruption wherever it exists” following allegations that it bribed doctors with £320m worth of cash and sexual favours in China, admitted on Monday that a GSK employee was disciplined in relation to the Polish allegations. GSK, which has repeatedly trumpeted its “zero tolerance” corruption policy as it battles to salvage its corporate reputation, only acknowledged the Polish allegations – which date back to 2010-12 – after an investigation by the BBC’s Panorama programme.”
The Guardian, April 16th 2014: “GlaxoSmithKline says it is investigating bribery claims in Jordan and Lebanon Allegations say GSK sales representatives bribed doctors by issuing free samples that they were then allowed to sell on”
Reuters, August 11th 2014: “Exclusive: GlaxoSmithKline faces fresh drug bribery claims in Syria Reuters last month reported allegations of corruption in GSK’s Syrian consumer business, which sells products including toothpaste and painkillers. The consumer operation was closed in 2012 due to the worsening civil war in the country. The Syrian prescription pharmaceuticals business remains operational, however, and GSK said it was committed to supplying safe and effective drugs and vaccines to patients in need. The new corruption claims involve alleged bribes paid to boost sales of various medicines, including ones to treat cancer and to prevent blood clots.”
Reuters, July 25th, 2015: “Exclusive: GSK faces new corruption allegations, this time in Romania The latest allegations say GSK paid Romanian doctors hundreds, and in one cases thousands, of euros between 2009 and 2012 for prescribing its medicines, including prostate treatments Avodart and Duodart and Parkinson’s disease drug Requip.
According to the email, the doctors were notionally paid for speaking engagements, but in three out of six cases, including the most highly paid one, they did not give any speech. The other three medics gave only one speech each, despite receiving multiple payments. GSK also provided doctors with many international trips and made payments to them under the guise of participation in advisory boards, the email said.”
Securities and Exchange Commission, September 30, 2016 (PDF): “GlaxoSmithKline plc (“GSK”) has agreed to pay $20 million to settle charges that it violated the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-toprescribe schemes to increase sales. An SEC investigation found that the schemes spanned a period of years and involved the transfer of money, gifts, and other things of value to health care professionals, which led to millions of dollars in increased sales of GSK pharmaceutical products to China’s state health institutions. The participants included certain complicit sales and marketing managers within GSK’s Chinabased subsidiaries. GSK failed to devise and maintain a sufficient system of internal accounting controls and lacked an effective anti-corruption compliance program to detect and prevent these schemes. As a result, the improper payments were not accurately reflected in GSK’s books and records. The SEC’s order finds that GSK violated the FCPA’s internal controls and books-and-records provisions. GSK consented to the order without admitting or denying the findings, and agreed to pay a $20 million civil penalty. GSK also agreed to provide status reports to the SEC for the next two years on its remediation and implementation of anti-corruption compliance measures.”
Moncef Slaoui leaves GSK in 2017, after having brought the company on the brink of disaster, together with the Chinese division. Together with GSK’s #1 through this period, the disgraced CEO Andrew Witty, one of the darkest figures in medicine’s history, Moncef Slaoui moves to become a Pharma investor aboard Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area. The rest is business as usual.
To be continued
LATER UPDATE 2, For the giggles: This is how Dork Suckerborg of Fakebook fame is doing damage control for this investigation
And this is how I do Suckerborg control. Guess what? Five minutes after I posted the thing below, Suckerborg re-instated the original post and deleted this from the group, Of course I posted it back in the comments of the original. Take your time to enjoy the multilevel beauty here, then tell me about 3d chess…
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
On May 9, 2016, in Atlanta, Georgia, the National Meningitis Association (www.nmaus.org) hosted a panel discussion, “Achieving Childhood Vaccine Success in the U.S.,” before its “Give Kids a Shot” Gala. The panel addressed a range of issues including parents who opt out of childhood vaccine requirements, physicians who stray from the recommended vaccine schedule, and the role of the media in creating or removing barriers to vaccination.
The panelists were (from left to right):
Paul Lee, M.D., Director of the International Adoption Program and Pediatric Travel Center at Winthrop-University Hospital in Mineola, New York (moderator).
Carol J. Baker, M.D., Professor of Pediatrics, Molecular Virology and Microbiology at Baylor College of Medicine, Houston, Texas.
Dorit Rubinstein Reiss, PhD., Professor of Law, University of California, Berkeley’s Hastings College of Law. Reiss favors legal liabilities for parents who opt for non-vaccination, and is noted for her support of California Senate Bill 277, which reduced exemptions to vaccination requirements for enrollment in California schools and daycare centers.
Arthur Caplan, PhD., Professor of Medical Ethics at NYU Langone Medical Center.
William Schaffner, M.D., Professor of Preventive Medicine and Infectious Diseases, Vanderbilt University School of Medicine.
Alison Singer, President of Autism Science Foundation.
Paul Offit, M.D., Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia.
At the 53:58 mark, Dr. Baker says:
“The fight, the battle is being fought — one family, one physician, one health center. That’s why we’re doing as well as we are. We’re talking about the minority [of vaccine refusers], and strategies against the minority. So I have the solution: Every study published in the last five years, you look at vaccine refusers, I’m not talking about people we can talk them into coming to terms, but refusers. (54:28 mark) Let’s just get rid of all the whites in the United States, because Houston is the most diverse city in the entire United States. There are seven Asian languages spoken in that city. I’ve been in the [racial] minority for more than 20 years in the city of Houston. The majority of them are what we all ‘Hispanics’ — it’s not a race or an ethnicity, it’s a political designation. A lot of them are from Central or South America, Mexico. Guess who wants to get vaccinated the most in Houston? Immigrants! It is the ‘well educated’ — in terms of pieces of paper and the paper on the wall — [who are the vaccine refusers], people that have been here for a long time, and it’s very unfortunate and. But I think we need not lose the big picture. The big picture is there are physicians out there — family practitioners, pediatricians, internists — talking one on one with either the older child — I don’t know when a child stops being a child. For me, I was 30, I wrote my mother and said ‘Hey, I’m a grown-up’. They’d already given me an M.D. degree by then, so it’s a good thing I was grown up. I think that we need to do things as an articulate media-trained group to encourage that conversation, and encourage our health care system to value what vaccines do. Give people enough time to talk to individual families. Most hesitant people, it’s absolutely right, someone said it earlier, some families are having ‘pre-natal visits’. That’s the time to talk about vaccines. This war is fought one on one, with individual families. We need to support those policies that give health care providers, nurses, I mean nurses are really really important, they’re the ones who are probably giving the shots, and if they’re not on board with accepting vaccines, then do you think they’re gonna be supportive of you recommending a vaccine? You have to have your whole [health care] practice situation on board.”
Three years after this, she got decorated by the Sabin Vaccine Institute with funding from Bill Gates.
The 2019 Albert B. Sabin Gold Medal ceremony was made possible in part by the Bill & Melinda Gates Foundation and Pfizer.
Dr. Baker is professor of pediatrics and of molecular virology and microbiology at Baylor College of Medicine in Houston, TX. Previously, she was head of the section of infectious diseases in the Department of Pediatrics at Baylor College of Medicine for 25 years. Dr. Baker is immediate past chair of the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices. She is a past president of the Infectious Diseases Society of America (IDSA) and the National Foundation for Infectious Diseases and was a member of the American Academy of Pediatrics Committee on Infectious Diseases from 1997-2012. Dr. Baker is a member of the National Academy of Medicine, a past-president of NFID and the Infectious Diseases Society of America (IDSA), and a former chair of the ACIP. Among numerous honors, she received the John P. Utz Leadership Award from NFID; the Mentor Award, Society Citation for outstanding achievements in the field of infectious disease, and the Alexander Fleming Award for Lifetime Achievement from IDSA; and the Albert Sabin Gold Medal Award from the Sabin Vaccine Institute.
“Baker’s discoveries about the relationship between infant GBS and maternal immunity, paired with her international advocacy work, have also led to the development of a much-needed vaccine, with candidates currently in clinical trials. She continues to work toward her ultimate goal of preventing this newborn disease through immunizing the mother during pregnancy.
A highly accomplished infectious diseases clinician, teacher and vaccinologist, Baker is known as “the Godmother of group B Streptococcus prevention.” Recognized for her work at a time when many physicians were against vaccinating expectant mothers, Baker’s advocacy for maternal immunization shaped a new medical culture in the United States, enabling doctors to save the lives of countless newborns.
Baker continues to advocate for the health of mothers and babies, such as shepherding the recommendation for routine pertussis booster vaccines for pregnant women while chairing the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices from 2009 to 2012.
“Dr. Baker’s pioneering work in group B Strep resulted in a more than 80 percent reduction of neonatal disease in the United States and her research is paving the way for the development of a long-overdue vaccine for this disease,” said Amy Finan, Sabin’s chief executive officer. “Each year, we select someone whose career exemplifies Dr. Sabin’s legacy – to ensure the benefits of vaccines reach every child. Today, we are glad to recognize not only a gifted researcher, but a champion who has made it her mission to ensure every baby gets a healthy start. Her life is a testament to the fact that real changes in immunization practices occur when research is paired with dedicated advocacy.”
Baker has authored or co-authored more than 400 peer-reviewed papers and book chapters. Notable among these is her work on the book, Vaccine-Preventable Disease: The Forgotten Story, where, alongside other respected vaccine experts, she highlighted the stories of innocent children who have suffered needlessly from vaccine-preventable diseases.
“I am honored to be awarded the distinguished Albert B. Sabin Gold Medal alongside fellow recipients whose work has saved so many lives,” Baker said. “I never planned to be a researcher. I became a doctor to help one patient at a time, but what I found was a calling to use the knowledge gained through research to advocate for life-saving interventions for mothers and babies. I sincerely thank the Sabin Vaccine Institute for the incredible honor of this award.”
The award was presented to Baker by Roger I. Glass, MD, PhD, director of the Fogarty International Center, 2015 recipient of the Sabin Award and husband of Dean Barbara J. Stoll, MD.
Awarded annually since 1994, the Albert B. Sabin Gold Medal recognizes champions who have made extraordinary contributions in the field of vaccinology or a complementary field. The award commemorates the legacy of Dr. Albert B. Sabin, who developed the oral polio vaccine that made monumental contributions to the near eradication of polio worldwide, then worked tirelessly to ensure the vaccine reached children around the world. Past Gold Medal recipients include Dr. Paul Offit, Dr. Anne Gershon and the late Dr. Maurice Hilleman, among many other distinguished vaccine experts.
An infectious diseases clinician, teacher and vaccinologist, Dr. Carol Baker’s discoveries about GBS immunity and pathogenesis helped shape the 1996 CDC consensus guidelines for routine GBS screening among pregnant women. Formerly the president of Infectious Diseases Society of America (IDSA) and the National Foundation for Infectious Diseases, she chaired multiple working groups within CDC’s Advisory Committee on Immunization Practices over the course of many years.
Active on numerous editorial boards, Dr. Baker has worked on five editions of the American Academy of Pediatrics’ Red Book (2000-2015), which provides reliable and clinically useful information on more than 200 childhood infectious diseases. She has received many honors and awards, including the Maurice Hilleman Award from the CDC; the Mentor, Society Citation and Alexander Fleming Lifetime Achievement awards from the IDSA; the Distinguished Physician Award from the Pediatric Infectious Diseases Society; and the Schneerson-Robbins Award in Vaccinology.
Baker earned a bachelor’s degree in English from the University of Southern California and received her medical, residency and fellowship training at Baylor College of Medicine and Harvard University.
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live.
The 2019 Albert B. Sabin Gold Medal ceremony was made possible in part by the Bill & Melinda Gates Foundation and Pfizer.” – Sabin Vaccine Institute
Here’s the whole thing, comments and likes turned off. If they take it down, let me know, I saved it.
UPDATE JUNE 7 2020:
Of course they took the original video uploads down and of course I got you covered.
Baker elected to national academy
“A highly accomplished infectious diseases clinician, educator, and vaccinologist, Carol Baker, MD, adjunct professor in the Department of Pediatrics in McGovern Medical School at UTHealth, has been elected to the prestigious National Academy of Medicine (NAM).
Baker was one of 100 professionals elected to the academy for outstanding professional achievement this week.
“This remarkable and well-deserved honor recognizes Dr. Baker’s lifelong contributions to mothers and babies,” said Barbara J. Stoll, MD, dean of McGovern Medical School and H. Wayne Hightower Distinguished Professor.
Baker was recognized for her expertise in group B streptococcal (GBS) epidemiology, pathogenesis, and prevention, and discovering the critical capsular component for conjugate vaccine development.
Baker has spent her career advocating on behalf of the health of mothers and babies. “I wanted to be a doctor since the age of 6, and I was determined to do something that helped children’s lives,” she said, adding that she was inspired to become a doctor by her mother – her parents met in college and were both pre-med.
She said she was “absolutely surprised and thrilled” at the incredible honor of being elected to NAM. “I hadn’t been that surprised since I was the only woman admitted to my class in medical school,” she added.
Baker earned her medical degree from Baylor College of Medicine in 1968, completed her internship at University of Southern California Medical Center, Los Angeles; and completed her residency and fellowship at Baylor as well as a research fellowship at Harvard. Her advocacy for maternal immunization shaped a new medical culture in the United States, enabling doctors to save the lives of countless newborns.
“Election to the Academy affirms that this was worthwhile,” she said. “But this honor reflects the whole team – those who work in the lab, the clinical research – I didn’t do this alone.”
Baker adds this distinction to many other awards, including the 2019 Albert B. Sabin Gold Medal, the Maurice Hilleman Award from the Center for Disease Control and Prevention; the Mentor, Society Citation, and Alexander Fleming Lifetime Achievement awards from the Infectious Diseases Society of America; the Distinguished Physician Award from the Pediatric Infectious Diseases Society; and the Schneerson-Robbins Award in Vaccinology.
Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, the NAM addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors. Membership in NAM is based upon distinguished professional achievement in a field related to medicine and health, as well as demonstrated and continued involvement with the issues of health care, prevention of disease, education, or research.” – Office of Communications UTH, October 23, 2019
Bonus: Now let’s find out who should be the main targets for the new vaccines
What happened to George Floyd was brutal and horrible and should never happen to anyone, anywhere. This is a moment of reckoning in the United States. We all need to really pause during this time and learn as best we can from it. Even before we saw this senseless death, COVID had already started to show us gaps and structural problems in our country. We are seeing black men die at a disproportionate rate. We know the way out of COVID-19 will be a vaccine, and it needs to go out equitably.